Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-α, in the treatment of Crohn’s disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy?
tumour necrosis factor-α
Document Type: Research Article
Royal Brisbane Hospital,
University of Melbourne Department of Medicine, Royal Melbourne Hospital, Melbourne, Victoria,
University of Queensland Department of Medicine, Mater Adult Hospital, Brisbane, Queensland,
Publication date: April 1, 2001